Alligator to Participate in Upcoming Investor Conferences
Lund, Sweden, September 23, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announces that Søren Bregenholt, Chief Execu ...
Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline
Lund, Sweden, September 2, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announces that the Company, in order to enabl ...
Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy
Lund, Sweden, September 2, 2021 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) and Scandion Oncology A/S (Nasdaq Stockholm: SCOL), toda ...
Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation
Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company has entered into a research collaboration and license agreem ...
Alligator Bioscience Announces New Senior Director of Communications & Investor Relations
Lund, Sweden, August 16, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Julie Silber has joined the company as t ...
Alligator Bioscience AB: Interim report January–June 2021
Positive Phase I data for ATOR-1017 ”As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on ...
Alligator Bioscience AB and Scandion Oncology A/S present promising preclinical data
Lund, Sweden, June 30, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Nasdaq Stockholm: SCOL) today announces ...
Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy
Lund, Sweden, June 7, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the scientific journal Expert Opinion on Bi ...
Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017
Lund, Sweden, June 4, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today presents novel supportive data from the ongoing Phase I cl ...